---
title: "Xolair (omalizumab) in allergic asthma: Safety questions"
description: "Safety questions on Xolair (omalizumab) in allergic asthma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings and Side effects. Questions: Do patients develop antibodies to Xolair in asthma? Does Xolair increase the risk of cancer? Does Xolair increase the risk of heart attack or stroke? Can Xolair cause Churg-Strauss syndrome or eosinophilic conditions? 4 further questions follow. 8 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/xolair--allergic-asthma/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xolair (omalizumab) in allergic asthma: Safety questions

Manufacturer: Genentech, Inc.; Novartis Pharmaceuticals Corporation  
Prescribing information: [Xolair](https://www.gene.com/download/pdf/xolair_prescribing.pdf)

Safety questions that apply to every indication of Xolair are on [Xolair (omalizumab), all indications: Safety](https://www.evicenter.com/medical-information/xolair/safety).

## Safety

<a id="xolair-antibodies"></a>

### Do patients develop antibodies to Xolair in asthma?

> “Antibodies to XOLAIR were detected in approximately 1/1723 (<0.1%) of patients treated 
> with XOLAIR in the clinical studies evaluated for asthma in patients 12 years of age and 
> older. In three pediatric studies, antibodies to XOLAIR were detected in one patient out of 
> 581 patients 6 to <12 years of age treated with XOLAIR and evaluated for antibodies.”

Source: [XOLAIR: Prescribing information, page 30, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=30)

## Warnings

<a id="xolair-cancer-risk"></a>

### Does Xolair increase the risk of cancer?

> “Malignancy: Malignant neoplasms were observed in 20 of 4127 (0.5%) XOLAIR-treated patients compared with 5 of 2236 (0.2%) control patients in clinical studies of adults and adolescents (≥12 years of age) with asthma and other allergic disorders. The observed malignancies in XOLAIR-treated patients were a variety of types, with breast, non-melanoma skin, prostate, melanoma, and parotid occurring more than once, and five other types occurring once each. The majority of patients were observed for less than 1 year. The impact of longer exposure to XOLAIR or use in patients at higher risk for malignancy (e.g., elderly, current smokers) is not known.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=Malignancy%3A%20Malignant%20neoplasms%20were%20observed,current%20smokers%29%20is%20not%20known.)

> “A subsequent 5-year observational study of 5007 XOLAIR-treated and 2829 non-XOLAIR-treated adolescent and adult patients with moderate to severe persistent asthma and a positive skin test reaction or in vitro reactivity to a perennial aeroallergen found that the incidence rates of primary malignancies (per 1000 patient years) were similar in both groups (12.3 vs 13.0, respectively). Study limitations which include the observational study design, the bias introduced by allowing enrollment of patients previously exposed to XOLAIR (88%), enrollment of patients (56%) while a history of cancer or a premalignant condition were study exclusion criteria, and the high study discontinuation rate (44%) preclude definitively ruling out a malignancy risk with XOLAIR.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=A%20subsequent%205%2Dyear%20observational%20study,a%20malignancy%20risk%20with%20XOLAIR.)

<a id="xolair-heart-attack-stroke"></a>

### Does Xolair increase the risk of heart attack or stroke?

> “Cardiovascular and Cerebrovascular Events from Clinical Studies in Patients with Asthma: A 5-year observational study was conducted in 5007 XOLAIR-treated and 2829 non-XOLAIR-treated patients ≥12 years of age with moderate to severe persistent asthma to evaluate the long-term safety of XOLAIR, including the risk of malignancy. The results suggest a potential increased risk of serious cardiovascular and cerebrovascular events in patients treated with XOLAIR, however the observational study design, the inclusion of patients previously exposed to XOLAIR (88% for a mean of 8 months), baseline imbalances in cardiovascular risk factors between the treatment groups, an inability to adjust for unmeasured risk factors, and the high study discontinuation rate (44%) limit the ability to quantify the magnitude of the risk.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=Cardiovascular%20and%20Cerebrovascular%20Events%20from,the%20magnitude%20of%20the%20risk.)

> “A higher incidence rate (per 1000 patient-years) of overall cardiovascular and 
> cerebrovascular serious adverse events (SAEs) was observed in XOLAIR-treated patients 
> (13.4) compared to non–XOLAIR-treated patients (8.1).  Increases in rates were observed for 
> transient ischemic attack (0.7 versus 0.1), myocardial infarction (2.1 versus 0.8), pulmonary 
> hypertension (0.5 versus 0), pulmonary embolism/venous thrombosis (3.2 versus 1.5), and 
> unstable angina (2.2 versus 1.4), while the rates observed for ischemic stroke and 
> cardiovascular death were similar among both study cohorts.”

Source: [XOLAIR: Prescribing information, page 22, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=22)

> “A pooled analysis of 25 randomized double-blind, placebo-controlled clinical trials of 8 to 52 
> weeks in duration was conducted to further evaluate the imbalance in cardiovascular and 
> cerebrovascular SAEs noted in the above observational cohort study.  A total of 
> 3342 XOLAIR-treated patients and 2895 placebo-treated patients were included in the 
> pooled analysis.  The patients had a mean age of 38 years, and were followed for a mean 
> duration of 6.8 months.  No notable imbalances were observed in the rates of cardiovascular 
> and cerebrovascular SAEs listed above.  However, the results of the pooled analysis were 
> based on a low number of events, slightly younger patients, and shorter duration of follow-up 
> than the observational cohort study; therefore, the results are insufficient to confirm or reject 
> the findings noted in the observational cohort study.”

Source: [XOLAIR: Prescribing information, page 22, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=22)

<a id="xolair-eosinophilic-conditions"></a>

### Can Xolair cause Churg-Strauss syndrome or eosinophilic conditions?

> “Eosinophilic Conditions: In rare cases, patients with asthma on therapy with XOLAIR may present with serious systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome. These events usually, but not always, have been associated with the reduction of oral corticosteroid therapy. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between XOLAIR and these underlying conditions has not been established.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=Eosinophilic%20Conditions%3A%20In%20rare%20cases%2C,conditions%20has%20not%20been%20established.)

<a id="xolair-stopping-steroids"></a>

### Can patients stop inhaled steroids when starting Xolair for asthma?

> “Corticosteroid Reduction: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of XOLAIR therapy for asthma. Decrease corticosteroids gradually under the direct supervision of a physician.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=Corticosteroid%20Reduction%3A%20Do%20not%20discontinue,direct%20supervision%20of%20a%20physician.)

> “Instruct patients receiving XOLAIR not to decrease the dose of, or stop taking any other 
> asthma, CRSwNP, CSU or IgE-mediated food allergy medications or allergen 
> immunotherapy unless otherwise instructed by their physician.”

Source: [XOLAIR: Prescribing information, page 43, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=43)

## Side effects

<a id="xolair-common-side-effects"></a>

### What are the most common side effects of Xolair for asthma?

> “Asthma: In patients ≥12 years of age, the most common adverse reactions (≥1% more frequent in XOLAIR-treated patients) were: arthralgia (8%), pain (general) (7%), leg pain (4%), fatigue (3%), dizziness (3%), fracture (2%), arm pain (2%), pruritus (2%), dermatitis (2%), and earache (2%). In pediatric patients 6 to <12 years of age, the most commonly observed adverse reactions (≥3% more frequent in XOLAIR-treated pediatric patients) were: nasopharyngitis, headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral gastroenteritis, arthropod bites, and epistaxis.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=Asthma%3A%20In%20patients%20%E2%89%A512%20years,gastroenteritis%2C%20arthropod%20bites%2C%20and%20epistaxis.)

> “There were no differences in the incidence of adverse reactions based on age (among patients under 65), gender, or race.<sup>4</sup>”

Source: [XOLAIR: Side Effects & Safety Profile, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/summary.html#:~:text=There%20were%20no%20differences%20in,patients%20under%2065%29%2C%20gender%2C%20or)

<a id="xolair-side-effects-children"></a>

### What side effects do children 6 to 11 have on Xolair?

> “The data described below reflect XOLAIR exposure for 926 patients 6 to <12 years of age, 
> including 583 patients exposed for six months and 292 exposed for one year or more, in 
> either placebo-controlled or other controlled asthma studies.  The mean age of pediatric 
> patients receiving XOLAIR was 8.8 years; 69% were male, and 64% were Caucasian.  
> Pediatric patients received XOLAIR 75 mg to 375 mg every 2 or 4 weeks or, for patients 
> assigned to control groups, standard therapy with or without a placebo.  No cases of 
> malignancy were reported in patients treated with XOLAIR in these trials. 
> The most common adverse reactions occurring at ≥3% in the pediatric patients receiving 
> XOLAIR and more frequently than in patients treated with placebo were nasopharyngitis, 
> headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral 
> gastroenteritis, arthropod bites, and epistaxis.  
> The adverse reactions most frequently resulting in clinical intervention (e.g., discontinuation 
> of XOLAIR, or the need for concomitant medication to treat an adverse event) were 
> bronchitis (0.2%), headache (0.2%) and urticaria (0.2%).  These reactions were observed at 
> similar rates in XOLAIR-treated patients and control patients.”

Source: [XOLAIR: Prescribing information, page 18, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=18)

<a id="xolair-injection-site-reactions"></a>

### How common are Xolair injection site reactions in asthma?

> “Injection Site Reactions: In adults and adolescents with asthma, injection site reactions of any severity occurred at a rate of 45% in XOLAIR-treated patients compared with 43% in placebo-treated patients. Severe injection site reactions occurred more frequently in XOLAIR-treated patients compared with patients in the placebo group (12% vs 9%, respectively). The types of injection site reactions in asthma studies included: bruising, redness, warmth, burning, stinging, itching, hive formation, pain, indurations, mass, and inflammation.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=Injection%20Site%20Reactions%3A%20In%20adults,pain%2C%20indurations%2C%20mass%2C%20and%20inflammation.)

> “The majority of injection site reactions occurred within 1 hour post injection, lasted less than 
> 8 days, and generally decreased in frequency at subsequent dosing visits.”

Source: [XOLAIR: Prescribing information, page 18, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=18)

## Related pages
- [Medical information: Xolair (omalizumab): Allergic asthma](https://www.evicenter.com/medical-information/xolair--allergic-asthma)
- [Indication](https://www.evicenter.com/medical-information/xolair--allergic-asthma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/xolair--allergic-asthma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/xolair--allergic-asthma/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/xolair--allergic-asthma/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/xolair--allergic-asthma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/xolair--allergic-asthma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/xolair--allergic-asthma/access-and-coverage)
